Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
SystImmune and Bristol Myers Squibb announced positive Phase 3 PANKU-Breast01 interim results showing iza-bren cut the risk of progression or death by 59% versus chemotherapy in HR+/HER2- advanced breast cancer, with median PFS of 8.2 vs 4.0 months (HR 0.41, p<0.0001). Confirmed objective response rate was 40.5% vs 20.2% for chemotherapy, with a manageable safety profile and only 1.1% adjudicated interstitial lung disease.
Key figures
- Drug Name
- izalontamab brengitecan (iza-bren, BL-B01D1)
- Phase Of Trial
- Phase 3
- P value
- p<0.0001
- Ild rate
- 1.1%
- Corr chemo
- 20.2%
- Hazard ratio
- 0.41
- Corr iza bren
- 40.5%
- Pfs risk reduction
- 59%
- Median dor chemo months
- 4.2
- Median pfs chemo months
- 4
- Discontinuation due traes
- 1.6%
- Median dor iza bren months
- 6.9
- Median followup pfs months
- 15.2
- Median pfs iza bren months
- 8.2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.